Allergan chops 1,400 jobs to cope with early Restasis generics
admin 3rd January 2018 Uncategorised 0Back in November, as investors were digesting the news that Allergan’s eye blockbuster Restasis could face early generic competition, CEO Brent Saunders promised investors that cost cuts were coming “rapidly.” Just over two months later, they’re here.
More: Allergan chops 1,400 jobs to cope with early Restasis generics
Source: fierce